Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer

CompletedOBSERVATIONAL
Enrollment

601

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Non-small Cell Lung Cancer
Trial Locations (33)

1415

Research Site, Buenos Aires

6720

Research Site, Mexico City

10103

Research Site, San José

10105

Research Site, Santo Domingo

13123

Research Site, Santiago

15036

Research Site, Lima

15074

Research Site, Lima

44260

Research Site, Monterrey

64700

Research Site, Guadalajara

70000

Research Site, Ho Chi Minh City

100000

Research Site, Hanoi

110111

Research Site, Bogotá

230002

Research Site, Montería -Cordoba

7500713

Research Site, Santiago

S2002RE

Research Site, Rosario - Santa Fe

Unknown

Research Site, Alexandria

Research Site, Cairo

Research Site, Tanta

Research Site, Kashmīr

Research Site, Kolkata

Research Site, Mumbai

Research Site, New Delhi

Research Site, Kuwait City

Research Site, City of Taguig

Research Site, Iliolo City

Research Site, Cebu City

Research Site, Makati

Research Site, Manila

Research Site, Quezon City

Research Site, Singapore

Research Site, Muang

Research Site, Bangkok

Research Site, Ankara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY